Estrogen, and other hormones and factors receptor status (Z17) ICD-10-CM
The Z17 code range covers estrogen, and other hormones and factors receptor status with 16 ICD-10-CM diagnosis codes. 10 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.
Code First
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists, there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation.
Codes in the Z17 Range 16 codes · 10 billable
- Z17 Estrogen, and other hormones and factors receptor statusNon-billable
- Z17.0 Estrogen receptor positive status [ER+]
- Z17.1 Estrogen receptor negative status [ER-]
- Z17.2 Progesterone receptor statusNon-billable
- Z17.21 Progesterone receptor positive status
- Z17.22 Progesterone receptor negative status
- Z17.3 Human epidermal growth factor 2 receptorNon-billable
- Z17.31 Human epidermal growth factor receptor 2 positive status
- Z17.32 Human epidermal growth factor receptor 2 negative status
- Z17.4 Combined receptor statusNon-billable
- Z17.41 Hormone receptor positiveNon-billable
- Z17.410 Hormone receptor positive with human epidermal growth factor receptor 2 positive status
- Z17.411 Hormone receptor positive with human epidermal growth factor receptor 2 negative status
- Z17.42 Hormone receptor negativeNon-billable
- Z17.420 Hormone receptor negative with human epidermal growth factor receptor 2 positive status
- Z17.421 Hormone receptor negative with human epidermal growth factor receptor 2 negative status
About the Z17 Code Range
ICD-10 code Z17 covers the receptor status of estrogen, progesterone, and human epidermal growth factor 2 (HER2), which are key markers often assessed in cancers like breast cancer to guide treatment decisions.
This range includes codes that specify whether estrogen receptors are positive (Z17.0) or negative (Z17.1), with synonyms such as hormone receptor positive malignant neoplasm of breast and HER2-positive carcinoma. It also identifies progesterone receptor status, including positive (Z17.21) and negative (Z17.22). Human epidermal growth factor receptor 2 (HER2) status is similarly captured with positive (Z17.31) and negative (Z17.32) designations. Combined hormone receptor and HER2 statuses are detailed under Z17.4 with subcodes describing hormone receptor positive or negative paired with specific HER2 statuses, helping clinicians and coders precisely document receptor profiles critical for personalized cancer care and prognosis. This coding allows accurate representation of hormone and growth factor receptor testing results in patient records.
Questions About This Page
How many billable codes are in the Z17 range?
Of the 16 codes in this range, 10 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.
What does the Z17 range classify?
The range classifies estrogen, and other hormones and factors receptor status. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.
